Christian is a seasoned Market Access professional with over 20 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.

Christian is a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs); he is also a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland.

Peter Rouse is an experienced health economist who joined MAP Biopharma in November 2019 as a Senior Consultant within the HEOR team. Peter has a background in health economic consulting, specialising in health economic modelling for early pricing of assets and HTA submissions, whilst also covering other areas of evidence generation and synthesis, including systematic literature reviews, (network) meta-analysis, preparation of global value dossier, HTA landscape analysis, local reimbursement dossier preparation, and outcomes research using patient-level data.

Peter has experience leading successful HTA submissions across Europe, including NICE, SMC and AWMSG, with focus on orphan products and gene therapies for rare disease areas and oncology. Prior to consultancy, Peter worked at the National Clinical Guideline Centre (NCGC) hosted by the Royal College of Physicians, specialising in discrete event simulation modelling for service delivery guidelines, whilst also working on disease specific projects such as type 2 diabetes, palliative care and asthma diagnosis and management. Peter holds a BA in Economics and International Relations from the University of Keele and an MSc in Health Economics and Decision Modelling from the University of Sheffield.

Nermina is a health economist specialising in the generation of evidence to highlight both the health benefits and the wider impact of health interventions. Nermina’s role focusses on two key areas of health economics and outcomes research: the assessment of clinical and cost-effectiveness of interventions and real-world evidence generation using worldwide secondary real-world data sources. Nermina designs pharmacoepidemiologic and pharmacoeconomic studies and conducts patient-level data and statistical analyses in R and STATA. In addition, Nermina develops economic models in a wide range of disease areas meaning that a range of modelling techniques are applied including decision trees, Markov models, patient simulation models and epidemiological models. Further, Nermina contributes to the authorship of health technology assessment submissions for worldwide regulatory bodies.
Nermina holds an MSc in Health Economics and Health Policy from The University of Birmingham and is a member of the Royal Economic Society.